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Abstract
Background: Choline kinase is the first enzyme in the CDP-choline pathway that synthesizes phosphatidylcholine, the major
phospholipid in eukaryotic cell membranes. In humans, choline kinase exists as three isoforms (CKa1, a2, and b). Specific
inhibition of CKa has been reported to selectively kill tumoral cells. Monoclonal and polyclonal antibodies against CKa used
in previous studies to detect the level of this isozyme in different cellular or biochemical contexts were able to detect either
the a1 or the a2 isoform.
Methodology/Principal Findings: In this study, an antiserum against CKa was produced by immunizing rabbits with
denatured, purified recombinant CKa2 full-length protein. This antiserum was highly specific for CKa when tested with
extracts from different cell lines, and there was no cross reactivity with purified CKb and other related proteins like human
ethanolamine kinases (EK) and yeast choline or ethanolamine kinases. The antiserum simultaneously detected both CKa1
and a2 isoforms in MCF-7 and HepG2 cell extracts, but not in HeLa, HCT-116, and mouse embryonic stem cell extracts.
Subsequent protein dot blot assay of total CKa in a human normal/tumor protein array of 30 tissue samples by using the
antiserum showed that CKa was not overexpressed in all tumor tissues when compared to their normal counterparts. Most
striking differences between tumor and normal CKa expression levels were observed in kidney (11-fold higher in tumor) and
liver (15-fold lower in tumor) samples.
Conclusion/Significance: Apart from its high sensitivity and specificity, the antiserum produced in this work, which does
not require further purification, has the advantage of co-detecting both a1 and a2 isoforms in cell extracts for direct
comparison of their expression levels.
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Introduction
Choline kinase (CK) (EC 2.7.1.32) catalyzes the phosphoryla-
tion of choline by ATP in the presence of Mg2+, yielding
phosphocholine and ADP [1]. CK commits choline to the so-
called Kennedy pathway for the biosynthesis of phosphatidylcho-
line (PtdCho) [2]. PtdCho is the predominant membrane lipid in
eukaryotes amounting to almost 50% of the total phospholipid
content [3]. Apart from its traditional role in the biosynthesis of
PtdCho, studies in the last decade have linked CK with muscular
dystrophy, bone deformities and cancer [4]. In mammals
including humans, CK exists as at least three isoforms, encoded
by two separate genes named ck-a and ck-b. While ck-b codes for a
single protein (CKb), ck-a undergoes alternative splicing and is
thus responsible for the production of two CK isoforms, a1 and a2
[1] which differ only by the presence of an additional stretch of 18
amino acids present in the a2 isoform [5] encoded by exon 3 of the
a2 transcript.
Increased CK activity was found in human breast cancer, and
overexpression of CK is frequently observed in lung, prostate and
colorectal cancers [6]. Elevated levels of CK activity in response to
treatment of rats with xenobiotics such as aromatic hydrocarbons
[1], or treatment of cultured cells with growth stimulants such as
serum, epidermal growth factors, or insulin [7,8], has been
reported. Recently, it was shown that overexpression of CK
increased the invasiveness and drug resistance of MCF-7 human
breast cancer cells [9]. Furthermore, CK suppression by RNA
interference in breast cancer cells reduced proliferation and
induced differentiation [10]. Based on these observations, CK
inhibition has been proposed as a potential anticancer strategy
[11,12,13]. More recent studies on the biological function of CK
isozymes revealed that CKa may play a more prominent role in
cancer development as compared to CKb, as only CKa was
upregulated in breast cancer cell lines [14], and specific depletion
of the CKa isoform by shRNA selectively induced apoptosis in
several tumor-derived cell lines without affecting the viability of
normal primary cells [15]. The CKa isoform has also been
proposed as a new prognostic marker for predicting the clinical
outcome in patients with non-small-cell lung cancer [16].
Immunoblot detection of CKa has become the primary means
to evaluate the level of this isoform in various normal and cancer
cell lines as well as upon treatments such as RNA interference.
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Polyclonal [17] and monoclonal [18] antibodies that specifically
recognize CKa have previously been developed. Commercial
polyclonal anti-CKa antibody has been used to assess the level of
this isoform in CKa knockout mice [19]. However, all the
antibodies used detected the expression of either CKa1 or a2 in
the same sample. The expression of CKa was generally referred to
a single band in Western detections and no attempt has been made
to investigate the differential expression of a1 and a2 in various
experimental settings.
In this work, a polyclonal antibody against human CKa was
generated in rabbits using recombinantly produced CKa2 as
antigen. The antiserum was tested for cross-reactivity with purified
human and yeast choline and ethanolamine kinase isoforms, and
the sensitivity was assessed by detecting variable amounts of
purified CKa2. The specificity of the antiserum was confirmed by
immunoblot detection of CKa in different cancer cell lines.
Subsequently, the antiserum was used in protein dot blot assays to
determine the level of total CKa and analyze its presence in 15
pairs of normal and tumor tissues.
Results
High sensitivity and specificity of CKa antiserum
To establish an effective working concentration, different
dilutions of the antiserum were used for the detection of purified
human CKa2 protein. Figure 1 shows the Western blot detection
of three different quantities (60, 6 and 0.6 ng) of CKa2 with four
different dilutions (1.0, 1.5, 2.0 and 2.56104 times) of antiserum.
The results indicate that 25000-fold dilution of the antiserum
(maximum dilution used in this experiment) was still sufficient to
detect the 6 ng band. The lowest CKa2 quantity used (0.6 ng) was
detectable by the 20000-fold dilution of the antiserum. However,
the signal of the 0.6 ng band was not much different when higher
concentrations of the antiserum were used. The results showed
that the antiserum was able to detect CKa2 protein at such low
concentration.
To investigate the specificity of the CKa antiserum against
proteins in the CK/EK family, it was tested for cross-reactivity
with multiple purified human and yeast CK/EK variants (as listed
in Table 1). The results in Figure 2 show that the antiserum was
very specific for CKa derivatives (hCKa1, D49N- and D84N-
hCKa2). The N-terminal truncation of CKa2 significantly
reduced the signal produced by the antiserum. No cross reactivity
with purified hCKb, D89N-hEK1, hEK2a, yCK, and yEK was
detected.
The CKa antiserum was subsequently tested with HeLa cell
extract. As shown in Figure 3A, CKa was detected with up to
20,000-fold dilution, and there was no apparent unspecific
detection of other proteins including human CKb, EK1 and
EK2, or other unknown human choline or ethanolamine kinases.
Only a single band was detected in HeLa cell extract although
both CKa1 and a2 could be detected by this antiserum. The band
detected in HeLa cell extract corresponded exactly to the positive
control, which was 6 ng of purified human CKa2, suggesting that
only this isoform was present in HeLa cells.
CKa antiserum also detects mouse choline kinase
CKa antiserum was tested with mouse embryonic stem cell
extract. The antiserum was also able to detect mouse choline
kinase without any unspecific detection as indicated by a single
band in Figure 3B. The size of the protein detected is in agreement
with the 49.9 kDa mouse choline kinase a1 isoform [5]. Blast
search in the GenBank database revealed that the mouse choline
kinase a1 isoform (accession number BAA88153) is highly similar
to the human CKa1 isoform, with a protein sequence identity of
88%.
CKa antiserum detects both a1 and a2 isoforms in
certain cancer cell lines
The presence of CKa was analyzed in three other human
cancer cell lines, namely MCF-7 (breast cancer), HCT-116 (colon
cancer) and HepG2 (liver cancer). Interestingly, both CKa1 and
a2 were detected in MCF-7 and HepG2 cell lysates (Figure 4). The
purified CKa1 and a2 enzymes, that were included as reference,
were clearly separated and the antiserum showed equal affinity
towards both isoforms as evidenced by the equal intensity of
signals. Based on its migration on the gel, the band detected in
HCT-116 cell lysate was likely to be CKa1. MCF-7 cell line
showed higher expression of total CKa compared to HCT-116
and HepG2 cells. The levels of CKa1 and a2 were very similar in
cells that expressed both isoforms. All the results presented above
showed that the antiserum was sensitive and specific for the
detection of CKa isoforms without requiring any purification.
CKa is differentially expressed in multiple human normal
and tumor tissues
The specificity of the CKa antiserum when tested on a series of
human cell lysates and mouse embryonic stem cell extract
supported its use in non-homogeneous samples such as for protein
dot blot analysis of total CKa. In this study, a commercial protein
array consisting of 30 different protein samples from human
normal and tumor tissues was used for detection of total CKa by
using the CKa antiserum. Stripping and re-probing of the array
produced identical results albeit with lower signal intensity. CKa
expression was detected in 70% of the tissue samples on the panel,
and the detected signal intensities of different tissues after
normalization with respect to the corresponding GAPDH signals
are presented in Figure 5A. The expression levels of CKa in
different human normal and tumor tissues displayed a very large
range with higher levels of CKa expression in normal lung and
kidney tumor tissues followed by lung tumor, normal small
intestine, normal thymus and normal liver tissues.
Tissues with detectable levels of CKa in both tumor and normal
samples were subjected to pairwise comparison. Figure 5B shows
that about half of the tissues compared showed significantly higher
expression of CKa in tumors. The most significant differences
between the level of CKa in tumor and normal tissues were
observed in kidney with 11-fold higher expression in tumor,
whereas in liver, 15-fold higher expression was found in normal
samples. According to the information provided by the manufac-
Figure 1. Immunoblot detection of purified CKa2 showing high
sensitivity of CKa antiserum. Varying amounts of purified human
CKa2 were detected using different dilutions of CKa antiserum. 6 ng of
CKa2 was still detectable with 25000-fold dilution of the antiserum.
Arrow indicates the location of hCKa2.
doi:10.1371/journal.pone.0012999.g001
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turer of the protein array, the kidney tumor sample was a well
differentiated clear cell carcinoma from a 44 year old female.
Discussion
Antibody against human CKa was raised in rabbits using
purified full length human CKa2 protein as the immunogen. The
antiserum showed high sensitivity and specificity for CKa1 and a2
isoforms, without purification of the IgG fraction, as evidenced by
its ability to detect minute amount of CKa protein, with no
apparent cross-reactivity with other human or yeast CK and EK
isoforms. Previous antibodies against human choline kinase were
generated by immunizations with either GST-purified full-length
CKa protein [17,18] or synthetic peptide [10]. However, all the
antibodies, either monoclonal or polyclonal, detected either CKa1
or a2 in the same sample. The first antibody raised against choline
kinase was a polyclonal antibody against rat CKa [7]. This
antibody detected choline kinase a1 and, to a lesser extent, a2 in
colon cancer tissues of rats treated with 1,2 dimethylhydrazine
[20]. However, the same antibody only detected a faint 52 kDa
protein that corresponded to the size of CKa2 in human normal
and cancer colon cells [21]. In this report, we showed that purified
CKa1 and a2 were separable in standard SDS-PAGE, and these
purified proteins could serve as a reference for simultaneous
detection of the two isoforms in cell lysates. Interestingly, only two
of the four cell lines tested in this work expressed detectable level of
both isoforms. It remains to be determined whether the expression
of CKa1 and a2 isoforms is cell cycle or cell type dependent, or
whether it is also governed by other factors such as growth factors
and carcinogens.
Although RT-PCR or quantitative real-time PCR have been
used to assess the level of CK expression [14], it is not possible to
design specific primers for human CKa1 because its whole cDNA
sequence is shared with the sequence of CKa2. The unique
properties of CKa antiserum combined with the purified CKa1
and a2 proteins as references, will be an attractive tool for accurate
quantification and comparison of total or individual CKa isoforms
in various cells, especially because the antiserum also showed
identical affinity towards both isoforms in our experiments. We
have previously shown that human CKa1 and a2 have very
distinct catalytic activities, the a2 isoform being about four times
more active than a1, with much higher affinity for choline [22].
Therefore, the differential detection and quantification of the two
isoforms is of critical importance for the design of a more specific
inhibitor that targets only the elevated isoform.
The specificity of CKa antiserum also makes it suitable for
immunoprecipitation of total CKa from cell extract to study the in
vivo properties of this isoform in terms of post-translational
modifications and interaction with other CK isoforms [23] or
proteins. Recently, RNA interference has been successfully em-
ployed to selectively knockdown different isoforms of CK [10,15,24].
The antiserum can provide confirmation of CKa silencing in such
experiments. Moreover, reactivity of the CKa antiserum with mouse
choline kinase will allow for broader applications of this antiserum as
mouse is widely used as an animal model for pharmacological,
developmental and immunological studies [25,26].
Total CKa was detectable in two thirds of the tissue samples
displayed on the protein array. This observation is in agreement
with Northern blot analyses of CKa mRNA levels in human,
mouse, and rat that showed it was ubiquitously expressed in
various tissues of the three mammalian species [23]. Overexpres-
sion of choline kinase has been reported to be a frequent feature in
human tumor-derived cell lines and in lung, prostate and
colorectal cancers [6]. On the contrary, the results from our
protein dot blot assay showed that overexpression of CKa was not
observed in all tumor tissues where only about 50% of tumor
samples expressed higher levels of CKa compared to their normal
tissues. These results are, however, explainable since only 17%,
47%, 56% and 48% of breast, colon, lung and prostate cancers,
Table 1. Proteins and expression plasmids used in this study.
Protein [reference] Expression plasmid Molecular weight (kDa)
Human CKa1 [5] pGEX-RB-hCKa1 50.1
Human CKa2 [5] pGEX-RB-hCKa2 52.2
Human CKb [5] pGEX-RB-hCKb 45.3
Human CKa2 truncated at the first 49 amino acids [22] pGEX-RB-D49N-hCKa2 47.5
Human CKa2 truncated at the first 84 amino acids (produced in this work) pGEX-RB-D84N-hCKa2 43.9
Human ethanolamine kinase 1 (EK1) truncated at the first 89 amino acids
(produced in this work based on [34])
pET-14b-D89N-hEK1 42.0
Human EK2a [34] pET-14b-hEK2a 44.8
Saccharomyces cerevisiae CK [35] pGEX-RB-yCK 66.3
Saccharomyces cerevisiae EK [36] pGEX-RB-yEK 61.7
pGEX-RB and pET-14b were used for expression as GST and 6x histidine fusion proteins, respectively.
doi:10.1371/journal.pone.0012999.t001
Figure 2. Immunoblot detection of human and baker’s yeast
choline and ethanolamine kinases showing isoform specificity
of CKa antiserum. Detection of purified hCKa1 (1), hCKa2 (2), hCKb
(3), D89N-hEK1 (4), hEK2a (5), D49N-hCKa2 (6), D84N-hCKa2 (7), yCK (8)
and yEK (9) were performed with 10000-fold dilution of CKa antiserum.
Each lane was loaded with 50 ng of purified protein. Lane M is
ChemiBlot molecular weight marker.
doi:10.1371/journal.pone.0012999.g002
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respectively, showed increased CKa levels [6,13]. The implication
of choline kinase in human cancer pathogenesis was not entirely
due to a higher expression level of this enzyme, but also to its
higher activity detected in cancer cells [13]. The choline kinase b
isoform, which is not detected by the CKa antiserum, or the more
active CKa2 alone could also contribute to the higher choline
kinase activity in cancer cells [21]. The higher choline kinase
activity can also result from post-translational activation such as
phosphorylation or positive regulation by interacting partners.
The use of protein array enabled us to analyze CKa levels in a
relatively large number of tissue samples. The array is particularly
applicable with the antiserum produced in this work since Western
blots did not show any cross reactivity with other human proteins,
and therefore the signal from the protein dot blot should reliably
reflect the level of total CKa. The use of the protein array also
bypassed the time-consuming sample collection step especially for
tissue samples from human volunteers. The protein array
screening strategy proved to be highly suitable for identifying
tissues with detectable and significantly different levels of CKa in
normal and tumor samples. Results obtained with the protein
panel could be confirmed by Western blot analysis of more
samples from the tissue of interest.
We note that the protein array may have disadvantages, such as
the limited sample number (only one) for each type of tissue, which
greatly affects the statistical reliability of any observation, and the
loss of signal intensity after stripping and re-probing, which limits
the use of the array for further probing with other antibodies. Use
of the CKa antibody can be extended to protein microarrays that
cover more tissue types and samples [27,28]. Our antiserum
reduces the risk of unspecific detection in non-homogenous
samples, and it can be used to determine the level of CKa
isoforms in different types and stages of cancer, as well as in
various samples such as blood plasma.
Based on the emerging evidences that specifically link CKa to
the pathogenesis and prognosis of various cancers [15,16,29,30], it
is apparent that more focus should be given to the detection of this
isoform. Our antibody provides the opportunity to study the
regulation of both CKa1 and a2 expression in different cells and
tissues through direct quantitative comparison of the expressed
protein pattern. More specifically, the antibody could potentially
be used to monitor the CKa expression during different stages of
cancer development and subsequently for monitoring tumor
response to treatments.
Materials and Methods
Expression and purification of human and yeast choline/
ethanolamine kinases
The cDNA sequences coding for the proteins of interest were
ligated into the NdeI and BamHI sites of pET-14b (Novagen) or
pGEX-RB [31] vectors for expression as 6x histidine or
glutathione S-transferase (GST) fusion proteins, respectively. The
proteins and their expression plasmids used in this study, together
with the predicted molecular masses of the CK subunits are listed
in Table 1. All proteins were expressed in Escherichia coli C41(DE3)
strain [32]. The culture was first grown at 37uC until OD600 nm of
0.8 to 1.0 was reached. Protein expression was induced by 0.3 to
1.0 mM (final concentration) of IPTG at 25uC for 16 hours.
Subsequently, the cells were harvested by centrifugation at
50006g for 20 minutes at 4uC. The cell pellet was re-suspended
in pre-chilled (4uC) lysis buffer containing 50 mM Tris-HCl
(pH 7.5), 300 mM NaCl, 5 mM EDTA, 10% glycerol, 1% Triton
Figure 4. Concurrent immunoblot detection of CKa1 and a2
isoforms in MCF-7 (lane 1) and HepG2 (lane 3) cell lysates. Only
CKa1 was detected in the HCT-116 cell lysate (lane 2). 5 ng of each
purified CKa1 and a2 were loaded as references (lane +). 50 mg of each
cell lysate were loaded and detection was performed with 10000-fold
dilution of CKa antiserum. Results are representative of triplicate
experiments with similar results.
doi:10.1371/journal.pone.0012999.g004
Figure 3. Immunoblot detection showing specificity of CKa antiserum in HeLa (A) and mouse embryonic stem cell (B) lysates. The
detection was performed with different dilutions of CKa antiserum for HeLa cell lysate. 6 ng of purified hCKa2 was used as the positive control (+).
10000-fold dilution of CKa antiserum was used for detection of mouse CKa in 50 mg of mouse embryonic stem cell protein lysate (E), using 50 mg of
HeLa cell protein extract as the positive control (H). M: ChemiBlot molecular weight marker. Results are representative of triplicate experiments with
similar results.
doi:10.1371/journal.pone.0012999.g003
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X-100, 5 mM b-mercaptoethanol, 0.5 mM phenylmethylsulpho-
nylfluoride (PMSF) and 1 tablet of CompleteTM protease inhibitor
cocktail (Roche) in every 50 ml of buffer. The lysis buffer used for
purification of His-tag protein was supplemented with 10 mM
imidazole to reduce non-specific binding. The cell suspension was
sonicated in an ice bath with short pulses of 1 second burst and 1
second pause for 1 to 4 minutes. After the sonication step, the cell
lysate was centrifuged at 150006g for 30 minutes (4uC) and the
supernatant was transferred into a new tube. The His-tagged and
GST-tagged proteins were purified under native conditions by
affinity binding to nickel-nitriloacetic acid (Ni-NTA) metal affinity
matrix (Qiagen), and Glutathione Sepharose 4B (GE Healthcare),
respectively. The matrix was washed with 20 bed volumes of wash
buffer (50 mM Tris-HCl (pH 7.5), 300 mM NaCl, 0.5% Triton
X-100 and 10% (v/v) glycerol). Proteins were eluted without the
affinity tags by overnight cleavage with thrombin (Serva
Electrophoresis). Protein concentration was determined by the
Bradford assay, and enzymes were stored at 280uC. All
purification steps were carried out at 4uC in a cold room.
Gel purification of antigen and antibody production
Affinity purified human CKa2 was run on a preparative 12%
SDS-PAGE gel at 70 mA for 3 hours in the cold room. After
Figure 5. Differential expression of CKa in human normal and tumor tissues. (A) Levels of total CKa in 30 human normal and tumor tissues.
The signal intensities (arbitrary unit) were normalized with respect to the corresponding GAPDH signals. (B) Pairwise comparison of tumor/normal
CKa levels. Only tissues showing detectable levels of CKa in both tumor and normal samples were analyzed. Positive and negative fold changes
indicate higher and lower expression in tumor, respectively. (C) CKa signal detected on the panel by using 20000-fold diluted CKa antiserum. (D)
GAPDH detection assay provided by the supplier; it was used for signal normalization. (E) Identities of protein spots on the panel.
doi:10.1371/journal.pone.0012999.g005
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Coomassie staining, the protein band corresponding to the size of
CKa2 was excised, sliced into smaller pieces (about
0.25 cm62 cm), and eluted from the gel using the Elutrap
electroelution system (Schleicher and Schuell) at 30 mA for
16 hours at 4uC with 1x TAE buffer. For production of polyclonal
CKa antibodies in rabbits, 1 mg of the eluted protein was used as
immunogen (Eurogentec, Belgium). The standard immunization
program recommended by the company was followed without
modification. The serum from the final bleeding (87 days after first
immunization) was used as antiserum for Western blot detection,
without isolation of the IgG fraction.
Cell cultures and preparation of cell lysates
Human HeLa (ATCC no. CCL-2), MCF-7 (ATCC no. HTB-
22), HCT-116 (ATCC no. CCL-247) and HepG2 (ATCC
no. HB-8065) cell lines were maintained in Dulbecco’s Modified
Eagle Medium (DMEM) with 10% (v/v) fetal calf serum and
supplemented with 100 U/ml of penicillin/streptomycin antibiotic
mix (Sigma), under standard conditions of 37uC and 5% CO2. To
prepare the cell lysates for Western blotting, culture medium was
removed and cells were washed once with PBS buffer. Protein was
extracted by Proteojet mammalian cell lysis buffer (Fermentas) and
quantified by the Bradford assay (Biorad). Mouse embryonic stem
cell extract was provided by Dr. Luo Ling Fei from the
Department of Developmental Biology, MPI-BPC, Germany.
Western blot, sensitivity and specificity analyses of CKa2
antiserum
Variable amounts of purified proteins or 50 mg of cell lysates
were separated on 12% SDS-PAGE and transferred onto
nitrocellulose membrane by using the ‘tank blot’ method [33].
The gel was placed on a nitrocellulose membrane (Schleicher and
Schuell) of equal size and sandwiched with 2 layers of Whatman
paper. The stack was transferred into the blot chamber (BioRad
Trans-Blot cells) filled with transfer buffer (20 mM Tris-base,
150 mM glycine, 20% (v/v) methanol) and electroblotted at
110 mA for 1.5 to 2 hours at 4uC. Successful protein transfer was
indicated by the blotting of pre-stained protein ladder (Invitrogen).
After the transfer step, the membrane was immersed in blocking
solution [Western buffer A (10 mM Tris-HCl (pH 7.5), 150 mM
NaCl, 0.1% (v/v) Tween 20), supplemented with 2% (w/v) milk
powder) and shaken gently for 1 hour at room temperature. After
removal of the blocking solution, the membrane was incubated
with a fresh blocking solution containing the primary antibody at a
specific dilution (1:10000 to 1:25000) for 1 hour. The membrane
was subsequently washed 3 times for 10 minutes with Western
buffer A followed by incubation with donkey anti-rabbit IgG
(Amersham) secondary antibody (dilution 1:5000) in blocking
solution for 45 minutes. The membrane was washed 6 times for 10
minutes with Western buffer A before standard enhanced
chemiluminescence (ECL) detection whereby the membrane was
incubated for one minute in a 1:1 mixture of the two ECL
solutions (Roche) and immediately analyzed on the Lumi-Imager
workstation (Boehringer).
Protein dot blot detection of CKa in human normal/
tumor tissue panel
Human normal/tumor protein array purchased from BioChain
Institute (catalog no. A1235712; lot no. A605122) was probed
with CKa antiserum at 1:20000 dilution according to the standard
Western detection protocol as described above. Based on the
information provided by the manufacturer, the protein array was
made by spotting the same amount of total protein from 15 pairs
of human normal and tumor tissues on a 10620 nylon membrane.
The protein array included two positive (normal placenta) and two
negative (water) control spots. All samples were spotted in
duplicate. The characteristics and donor information of protein
samples on the panel were provided by the manufacturer. Western
detection of control protein, glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH), on the same batch of protein array was
carried out by the manufacturer and the result was provided
together with the product. Signals detected on the panels were
analyzed by using ImageJ version 1.43 U software (downloaded
from http://rsbweb.nih.gov/ij/). Briefly, the background was
subtracted with rolling radius of 50 pixels under light background
selection and the color of the image was inverted. The integrated
densities of dots representing each tissue were measured in
triplicate and the average values were then normalized to the
corresponding integrated densities of GAPDH. Detectable limit
was defined as the signal intensities that were at least three times
higher than the signal intensity of background. All values were
expressed as means 6 SD. Statistical analysis was performed with
GraphPad Prism 5. CKa expressions in normal and tumor tissues
were compared using the one-way analysis of variance (ANOVA).
P-values ,0.05 were considered as statistically significant.
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